Cyclooxygenase-2 Expression in Urinary Bladder Transitional Cell Carcinoma and its Association with Clinicopathological Characteristics
Authors:
- Golrokh OlfatiGOGolrokh Olfati
- Seyed Ali AhmadiSASeyed Ali Ahmadi
- Sudabeh YusefniaSYSudabeh Yusefnia
Open Access
- 30 August 2013
- journal article
- research article
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 14 (8) , 4539-4543
Abstract
Cyclooxygenase-2 Expression in Urinary Bladder Transitional Cell Carcinoma and its Association with Clinicopathological Characteristics Cyclooxygenase-2;urinary bladder;transitional cell carcinoma;immunohistochemistry; Background: Transitional cell carcinoma (TCC) is the most predominant type of urinary bladder tumor. As cyclooxygenase (COX)-2 is recently introduced as an attractive target molecule in bladder TCC, we evaluated the immunohistochemical expression of this marker and its association with several clinicopathological characteristics. Materials and Methods: This cross-sectional study was performed in the Pathology department of Sina Hospital in Tehran, Iran during 2006-2011. Ninety-two paraffin embedded blocks were selected from patients with urinary bladder TCC who underwent cystectomy or transurethral resection (TUR). Then, we assessed COX-2 expression by immunohistochemical staining using antibody against COX-2. Staining in more than 5% of tumor cells was considered as positive expression. Results: COX-2 was expressed in 50 % of our patients. This marker was markedly expressed in high grade bladder TCC (62.1%) versus other grades and there was statistically a significant difference in COX-2 expression between various grades (p=0.008). In addition, patients' age, lymphatic and perineurial invasion were associated with the expression of COX-2 (p=0.001, 0.015 and 0.039, respectively). However, other parameters such as stage, tumor size, venous invasion and lymph node metastasis did not show any significant relationship with this marker (all, p>0.05). Conclusions: COX-2 was expressed in urinary bladder TCC especially in high grade forms, advocating its probable role in the differentiation of this tumor. Accordingly, COX-2 could be a valuable biological target molecule in the evaluation and treatment of patients with bladder TCC.Keywords
This publication has 25 references indexed in Scilit:
- Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for urinary bladder cancer in North IndiaSurgery, 2011
- Effects of Short-term Celecoxib Treatment in Patients with Invasive Transitional Cell Carcinoma of the Urinary BladderMolecular Cancer Therapeutics, 2010
- The Expression of Cyclooxygenase-2 and Survivin in Urinary Bladder Transitional Cell CarcinomaThe Korean Journal of Pathology, 2009
- Expression of Cyclooxygenase-2 in Normal Urothelium, and Superficial and Advanced Transitional Cell Carcinoma of BladderJournal of Urology, 2007
- Relation between Cyclooxygenase-2 Expression and Clinicopathologic Parameters with Patient Prognosis in Transitional Cell Carcinoma of the BladderUrologia Internationalis, 2006
- A Histopathologic Investigation of PGE2 Pathways as Predictors of Proliferation and Invasion in Urothelial Carcinomas of the BladderEuropean Urology, 2003
- Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancerUrology, 2002
- Celecoxib: A Specific COX-2 Inhibitor with Anticancer PropertiesCancer Control, 2002
- Enhanced Expression of Cyclooxygenase-2 in High Grade Human Transitional Cell Bladder CarcinomasThe American Journal of Pathology, 2000
- The World Health Organization/International Society of Urological Pathology Consensus Classification of Urothelial (Transitional Cell) Neoplasms of the Urinary BladderAmerican Journal of Surgical Pathology, 1998